Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Moore HCF, et al. Among authors: gomez hl. J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185. J Natl Cancer Inst. 2019. PMID: 30371800 Free PMC article.
Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C. Gómez H, et al. J Clin Oncol. 1998 Jul;16(7):2352-8. doi: 10.1200/JCO.1998.16.7.2352. J Clin Oncol. 1998. PMID: 9667250 Clinical Trial.
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Hess KR, et al. Among authors: gomez hl. J Clin Oncol. 2006 Sep 10;24(26):4236-44. doi: 10.1200/JCO.2006.05.6861. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896004
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. Liedtke C, et al. Among authors: gomez hl. Breast Cancer Res. 2008;10(2):R27. doi: 10.1186/bcr1984. Epub 2008 Mar 27. Breast Cancer Res. 2008. PMID: 18371219 Free PMC article.
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Hortobagyi GN, et al. Among authors: gomez hl. Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8. Breast Cancer Res Treat. 2010. PMID: 20454927 Clinical Trial.
172 results